Lanthanum carbonate
- Generic Name
- Lanthanum carbonate
- Brand Names
- Fosrenol
- Drug Type
- Small Molecule
- Chemical Formula
- C3La2O9
- CAS Number
- 587-26-8
- Unique Ingredient Identifier
- 0M78EU4V9H
- Background
Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name Fosrenol by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led to severe choking. It is prescribed for t...
- Indication
Used to reduce serum phosphate in patients with end stage renal disease (ESRD).
- Associated Conditions
- Hyperphosphataemia
- Associated Therapies
- -
Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2011-04-26
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Geoffrey Block
- Target Recruit Count
- 15
- Registration Number
- NCT01341678
- Locations
- 🇺🇸
Denver Nephrologists, PC, Denver, Colorado, United States
Efficacy of Lanthanum Carbonate in Calciphylaxis
- Conditions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 12
- Registration Number
- NCT01289626
- Locations
- 🇺🇸
University of Wisconsin Hospitals, Madison, Wisconsin, United States
Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy
- Conditions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Shire
- Target Recruit Count
- 66
- Registration Number
- NCT01130831
- Locations
- 🇩🇪
Dialyse am Treptower Park, Berlin, Germany
🇩🇪Dialyse Alsfeld, Alsfeld, Germany
🇩🇪Nephrologische Praxis Altötting-Burghausen, Altötting, Germany
Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 35
- Registration Number
- NCT01128179
- Locations
- 🇫🇷
Dr Pablo Urena Torres, Saint Ouen, Paris, France
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Shire
- Target Recruit Count
- 31
- Registration Number
- NCT00875017
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
- Conditions
- Interventions
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Myles Wolf
- Target Recruit Count
- 43
- Registration Number
- NCT00843349
- Locations
- 🇺🇸
University of Miami Hospital, Miami, Florida, United States
Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- Ineos Healthcare Limited
- Target Recruit Count
- 657
- Registration Number
- NCT00841126
- Locations
- 🇨🇦
William Osler Health Centre, Brampton, Ontario, Canada
🇺🇸Tidewater Kidney Specialists, Virginia Beach, Virginia, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
- Conditions
- Interventions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Denver Nephrologists, P.C.
- Target Recruit Count
- 148
- Registration Number
- NCT00785629
- Locations
- 🇺🇸
Denver Nephrologists, PC, Denver, Colorado, United States
Long-term Effect of Lanthanum Carbonate on Bone
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Shire
- Target Recruit Count
- 34
- Registration Number
- NCT00557323
- Locations
- 🇺🇸
Hypertension & Nephrology, Inc., Providence, Rhode Island, United States
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧St. Helier Hospital, Carshalton, United Kingdom
Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Shire
- Target Recruit Count
- 68
- Registration Number
- NCT00452478
- Locations
- 🇧🇪
Ziekenhuis Zuid Oost Limburg, Genk, Belgium
🇩🇰Frederica Sygehus, Fredericia, Denmark
🇩🇰Sygehus Viborg, Viborg, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.